PMID- 22038216
OWN - NLM
STAT- MEDLINE
DCOM- 20120315
LR  - 20191112
IS  - 1897-5631 (Electronic)
IS  - 0239-8508 (Linking)
VI  - 49
IP  - 3
DP  - 2011
TI  - Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations 
      with clinicopathologic features.
PG  - 389-97
AB  - The aim of this study was to evaluate the expression of COX-2 and Bcl-2 in 
      primary fallopian tube carcinoma (PFTC), as well as their correlations with 
      clinicopathologic features. We studied a cohort of 33 patients with a 
      pathological diagnosis of PFTC. Thirty normal tubal tissues used for controls 
      were obtained from patients diagnosed with uterine myomas. Expression analysis 
      for COX-2 and Bcl-2 was performed using the immunohistochemical technique. The 
      rate of preoperative diagnosis was 18.2%. With a median survival of 61.0 months 
      (95% CI: 43.2 to 78.8 months), the estimated five-year overall survival rate in 
      the 33 patients was 39.0%. Increased expression of COX-2 and Bcl-2 was observed 
      in tumor specimens compared to normal controls (p = 0.026; p = 0.003). The 
      expression rate of COX-2 in node-positive tumors was significantly higher than 
      that of node-negative tumors (p = 0.024). Moreover, the expression rate of COX-2 
      was statistically significantly higher in patients with infiltration through the 
      serosa (p = 0.019). Positive significant associations were observed between Bcl-2 
      staining index and FIGO stage (p = 0.015), and between Bcl-2 staining and lymph 
      node metastasis (p = 0.010). There was a significant correlation between COX-2 
      expression and Bcl-2 staining index (r = 0.517, p = 0.002). We conclude that 
      COX-2 and Bcl-2 may potentially be useful prognostic markers for PFTC. The exact 
      molecular mechanism for correlations between COX-2 and Bcl-2 remains to be 
      elucidated.
FAU - Wang, Fang
AU  - Wang F
AD  - Department of Oncology, First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui, China.
FAU - Sun, Guo-Ping
AU  - Sun GP
FAU - Zou, Yan-Feng
AU  - Zou YF
FAU - Wu, Qiang
AU  - Wu Q
FAU - Wu, Hong-Yang
AU  - Wu HY
FAU - Wu, Ji-Feng
AU  - Wu JF
FAU - Zhou, Jia-De
AU  - Zhou JD
FAU - Chen, Ke
AU  - Chen K
FAU - Zhang, Xiu-Shan
AU  - Zhang XS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Folia Histochem Cytobiol
JT  - Folia histochemica et cytobiologica
JID - 8502651
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Cohort Studies
MH  - Cyclooxygenase 2/*metabolism
MH  - Fallopian Tube Neoplasms/diagnosis/*metabolism/pathology
MH  - Fallopian Tubes/cytology/*metabolism/*pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Proto-Oncogene Proteins c-bcl-2/*metabolism
MH  - Survival Rate
EDAT- 2011/11/01 06:00
MHDA- 2012/03/16 06:00
CRDT- 2011/11/01 06:00
PHST- 2011/11/01 06:00 [entrez]
PHST- 2011/11/01 06:00 [pubmed]
PHST- 2012/03/16 06:00 [medline]
AID - 10.5603/fhc.2011.0055 [doi]
PST - ppublish
SO  - Folia Histochem Cytobiol. 2011;49(3):389-97. doi: 10.5603/fhc.2011.0055.